Drugs in Context最新文献

{"title":"Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study.","authors":"Tiago Torres, Paulo Varela, Pedro Mendes Bastos, Sofia Magina, Martinha Henrique, Paulo Ferreira","doi":"10.7573/dic.2023-12-5","DOIUrl":"10.7573/dic.2023-12-5","url":null,"abstract":"<p><strong>Background: </strong>Real-world evidence plays a pivotal role in validating the efficacy of biologic drugs beyond the controlled environment of randomized trials. This study aimed to evaluate the effectiveness of tildrakizumab in treating moderate-to-severe psoriasis within a real-world setting over a 52-week period in Portugal.</p><p><strong>Methods: </strong>This multicentric, prospective, observational study included adult patients with moderate-to-severe psoriasis. All participants received tildrakizumab 100 mg at weeks 0 and 4, followed by a maintenance dose every 12 weeks, and were monitored for 52 weeks. Primary endpoints were determined based on Psoriasis Area and Severity Index (PASI) assessments at baseline, 16 (±2) weeks, 28 (±2) weeks and 52 (±2) weeks.</p><p><strong>Results: </strong>A total of 54 patients were enrolled in the study (56% men, mean age of 50.3 ± 14.4 years). Half of the sample (<i>n</i>=27) had no prior experience with biologic treatments. About 74% of patients (<i>n</i>=40) presented at least one comorbidity during the study, with psoriatic arthritis being the most prevalent (29.6%). By week 52, there was a significant decrease in the mean PASI from 17.8±10.3 at baseline to 1.3±1.9 (<i>p</i><0.001), indicating an overall improvement of 93%. By week 52, more than 85% of patients attained PASI ≤5, more than 80% reached PASI ≤3, and nearly 60% achieved PASI ≤1. Infections were observed in 9.3% of patients, and one patient required hospitalization (1.9%). The cumulative proportion of patients continuing treatment at 52 weeks was 88.9%.</p><p><strong>Conclusions: </strong>This study demonstrates that tildrakizumab is an effective and safe agent for the treatment of moderate-to-severe psoriasis in a diverse, real-world setting.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"13 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140178665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of post-contrast kidney injury in patients with cancer.","authors":"Emanuele Grassedonio, Lorena Incorvaia, Marco Guarneri, Fabio Guagnini, Massimo Midiri","doi":"10.7573/dic.2023-11-2","DOIUrl":"10.7573/dic.2023-11-2","url":null,"abstract":"<p><p>Post-contrast acute kidney injury is defined as a nephropathy with an increase in serum creatinine of >0.3 mg/dL (or >26.5 μmol/L) or >1.5-times the baseline within 48-72 h of intravascular administration of a contrast medium. Patients with cancer have an increased risk of post-contrast acute kidney injury not only related to the frequent use of contrast medium for computed tomography scans but also to other factors, including the type of tumour, age, oncological therapies, use of other nephrotoxic agents and dehydration. Preventive strategies were developed and may be applied to different risk profiles. Patients at risk may be detected by recently published risk scores.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"13 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140179388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences.","authors":"Bernardo Rossini, Nicola Cecchi, Felice Clemente, Maria Rosaria De Paolis, Stefan Hohaus, Vanessa Innao, Mariano Lucignano, Roberto Massaiu, Giovanna Palumbo, Gian Matteo Rigolin, Francesca Gaia Rossi, Luisa Verga, Attilio Guarini","doi":"10.7573/dic.2023-9-4","DOIUrl":"10.7573/dic.2023-9-4","url":null,"abstract":"<p><p>Castleman disease (CD) is a group of lymphoproliferative disorders that share common histopathological features yet have widely different aetiologies, clinical features and grades of severity as well as treatments and outcomes. Siltuximab is currently the only therapy approved by the FDA and EMA for idiopathic multicentric CD and is recommended as first-line therapy in treatment guidelines. Despite the extensive characterization of siltuximab treatment in clinical trials, available evidence from real-world practice is still scant. This collection of clinical experiences focuses on patients treated with siltuximab therapy, particularly regarding the idiopathic multicentric CD diagnostic work-up, and on treatment administration in patients with complex disease entering differential diagnosis with CD or concomitant diseases. Thus, these data help further characterize and improve the use of siltuximab in real practice in terms of effectiveness and safety of long-term administration as well as consequences of treatment interruption.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"13 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140179389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences.","authors":"","doi":"10.7573/dic.2023-4-5","DOIUrl":"https://doi.org/10.7573/dic.2023-4-5","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.7573/dic.2023-9-4.].</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"13 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11186603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune findings in patients with silicosis in Spain.","authors":"Coral González Fernández, Jose Antonio Ros Lucas, Maria Molina Molina, Juan Rigual Bobillo, Rogelio Alejandro García Montenegro, Raquel Fernández González, Ana Jaureguiza Oriol, Jose Abal Arca","doi":"10.7573/dic.2023-11-1","DOIUrl":"10.7573/dic.2023-11-1","url":null,"abstract":"<p><strong>Background: </strong>Occupational exposure to silica is related to autoimmune diseases and features of autoimmunity, mainly autoantibodies. The study objectives were to estimate the prevalence of silicosis with associated autoimmune findings or diagnosed autoimmune diseases in Spain, and to assess the clinical and functional characteristics of affected patients.</p><p><strong>Methods: </strong>This is a multicentre prospective study in patients diagnosed with silicosis. Autoantibodies analysed were antinuclear antibodies, isotypes IgA, IgM and IgG, rheumatoid factor, anticyclic citrullinated peptide, anti-Scl70, anti-Ro, and anti-LA. Pulmonary function tests were performed.</p><p><strong>Results: </strong>Autoimmunity was assessed in 105 patients. Autoimmune findings were recorded in 29 (27%) patients, including antinuclear antibodies (<i>n</i>=21), anti-Ro (<i>n</i>=7), rheumatoid factor (<i>n</i>=5) and anti-Scl70 (<i>n</i>=3). Autoimmune disease was diagnosed in 16 (15%) patients, mainly rheumatoid arthritis (<i>n</i>=7) and systemic lupus erythematosus (<i>n</i>=4). Patients with silicosis and autoimmune findings had a lower mean time of exposure to silica and showed a trend toward lower values in pulmonary function tests.</p><p><strong>Conclusions: </strong>Autoimmune findings and diagnosis of autoimmune diseases were frequent in patients with silicosis in Spain.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"13 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR⁺/HER2^- metastatic breast cancer: a prospective, monocentric study.","authors":"Raffaella Palumbo, Erica Quaquarini, Giuseppe Saltalamacchia, Alberto Malovini, Pietro Lapidari, Barbara Tagliaferri, Ludovica Mollica, Cristina Maria Teragni, Chiara Barletta, Laura Deborah Locati, Federico Sottotetti","doi":"10.7573/dic.2023-7-5","DOIUrl":"10.7573/dic.2023-7-5","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most frequent tumour worldwide, and the HR⁺/HER2^- subtype is the most common. For this tumour type, endocrine therapy (ET) is the mainstay of treatment. The association of ET and CDK4/6 inhibitors (CDK4/6i) represents the gold standard for first-line or second-line therapies. However, the optimal therapeutic strategy after CDK4/6i progression is still a matter of debate, with several randomized clinical trials still ongoing.</p><p><strong>Patients and methods: </strong>This is an observational, prospective, real-world study including women with HR⁺/HER2^- metastatic breast cancer progressing to palbociclib plus ET. Patients received either ET or chemotherapy (CT). The primary objective was the evaluation of efficacy of the different therapeutic strategies after palbociclib in terms of median progression-free survival 2. Secondary objectives were the activity of therapeutic strategies measured with the clinical benefit rate, evaluation of the parameters used for the treatment choice, and progression-free survival 1 related to palbociclib plus ET treatment.</p><p><strong>Results: </strong>Overall, 48 patients (median age 53, range 33-78 years) were included. The median progression-free survival 2 was of 5 months in the overall cohort (95% CI 4-48 months) with a statistically significant difference between the two therapeutic strategies adopted (ET <i>versus</i> CT, 10 months <i>versus</i> 5 months, respectively). Regarding secondary objectives, the clinical benefit rate was 55.2% in the CT cohort and 50% in ET. Moreover, women treated with CT had a greater number of visceral metastases and a shorter median progression-free survival 1 than patients who received ET.</p><p><strong>Conclusions: </strong>ET and CT represent two possible therapeutic alternatives for patients progressing on CDK4/6i plus ET. The choice is based on clinical parameters, with a potential preference for ET.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"13 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10852029/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic liver disease and management with silymarin: an introductory review of a clinical case collection.","authors":"Francesco Angelico","doi":"10.7573/dic.2023-7-4","DOIUrl":"10.7573/dic.2023-7-4","url":null,"abstract":"<p><p>Chronic liver disease (CLD) is a significant global health concern and generally leads to fibrosis, cirrhosis and hepatocellular carcinoma. Various factors, such as metabolic abnormalities, viral infections, alcoholism, genetics and autoimmune responses, contribute to liver damage. CLD is characterized by different phenotypes, including non-alcoholic fatty liver disease, metabolic-associated fatty liver disease, drug-induced liver injury and alcoholic liver disease. These conditions have seen an increase in comorbidities and hospitalizations over the past decade, imposing a substantial burden on patients and healthcare systems. Understanding the underlying mechanisms of liver injury is crucial for effective management and reducing the clinical and economic burden of CLD. Although several attempts have been evaluated to find a drug therapy option for the management of non-alcoholic fatty liver disease and metabolic-associated fatty liver disease, there is no effective drug approved to date. However, different studies have demonstrated that silymarin, the milk thistle extract, could exert hepatoprotective, antioxidant, anti-inflammatory and antifibrotic properties and should therefore be considered an efficacious, tolerable and promising herbal product for the management of liver activity in CLDs. This review discusses the clinical features, diagnosis and available treatments for major liver diseases, acting as an introduction to a clinical case collection based on the management and treatment of major liver diseases with silymarin. This article is part of the <i>Current clinical use of silymarin in the treatment of toxic liver diseases: a case series</i> Special Issue: https://www.drugsincontext.com/special_issues/current-clinical-use-of-silymarin-in-the-treatment-of-toxic-liver-diseases-a-case-series.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"13 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10852028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Vulnerable period in heart failure: a window of opportunity for the optimization of treatment - a statement by Mexican experts.","authors":"","doi":"10.7573/dic.2024-2-5","DOIUrl":"https://doi.org/10.7573/dic.2024-2-5","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.7573/dic.2023-8-1.].</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"13 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11006242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The magnitude and predictors of self-medication amongst street dwellers in Ethiopia: a multicentre study.","authors":"Tirsit Ketsela Zeleke, Bekalu Dessie Alamirew, Zegaye Agmassie Bazezew, Muluken Adela Alemu, Abdisa Gemedi Jara, Rahel Belete Abebe","doi":"10.7573/dic.2023-7-2","DOIUrl":"10.7573/dic.2023-7-2","url":null,"abstract":"<p><strong>Background: </strong>Low levels of living standards amongst street dwellers worldwide limit their access to conventional healthcare services, resulting in self-medication use for the treatment of an illness. Nevertheless, self-medication use has risks, including adverse drug reactions, increased polypharmacy, drug resistance, drug dependence, drug interactions and incorrect diagnosis. Ethiopia has a large street-dwelling community; however, there are no studies conducted in Ethiopia assessing self-medication use amongst street dwellers. This study provides insight into self-medication use and predictors amongst street dwellers in Ethiopia.</p><p><strong>Methods: </strong>A community-based, multicentre cross- sectional study was conducted amongst street dwellers from 1 September 2022 to 1 February 2023 at community drug-retail outlets in the three major cities in the Amhara region of Ethiopia. The data were obtained using an interviewer-administered questionnaire. Frequencies and percentages of descriptive statistics were calculated. Bivariable and multivariable logistic regression analyses were employed to indicate predictors of self-medication use. To determine statistical significance, a 95% confidence interval with a <i>p</i> value below 0.05 was utilized.</p><p><strong>Results: </strong>The prevalence of self-medication use was 67.4%. Time and financial savings were reported as the reasons for most self-medication use. The most commonly reported illnesses for which people sought self-medication were gastrointestinal diseases. Low monthly income (adjusted OR 3.72, 95% CI 2.34-5.91) and residing near sewage areas (adjusted OR 3.37, 95% CI 2.03-5.58) were significantly associated with self-medication use.</p><p><strong>Conclusion: </strong>Street dwellers had a high rate of self- medication use. Residing near sewage areas and having a low level of income were factors in self-medication use. Gastrointestinal diseases, respiratory ailments and dermatological conditions were the most frequently reported complaints, whereas antimicrobials and anthelmintics were the most commonly used medications. We recommend that healthcare services enhance outreach programmes to the most vulnerable people, such as street dwellers, especially those with lower monthly incomes and who live near sewage areas, to reduce self-medication rates.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"13 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10803126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139541861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diuretic resistance and the role of albumin in congestive heart failure.","authors":"Carol Fernandez Hazim, Gustavo Duarte, Ana P Urena, Swati Jain, Rishabh Mishra, Timothy J Vittorio, Miguel Rodriguez-Guerra","doi":"10.7573/dic.2023-6-5","DOIUrl":"10.7573/dic.2023-6-5","url":null,"abstract":"<p><p>Diuresis with loop diuretics is the mainstay treatment for volume optimization in patients with congestive heart failure, in which perfusion and volume expansion play a crucial role. There are robust guidelines with extensive evidence for the management of heart failure; however, clear guidance is needed for patients who do not respond to standard diuretic treatment. Diuretic resistance (DR) can be defined as an insufficient quantity of natriuresis with proper diuretic therapy. A combination of diuretic regimens is used to overcome DR and, more recently, SGLT2 inhibitors have been shown to improve diuresis. Despite DR being relatively common, it is challenging to treat and there remains a notable lack of substantial data guiding its management. Moreover, DR has been linked with poor prognosis. This review aims to expose the multiple approaches for treatment of patients with DR and the importance of intravascular volume expansion in the response to therapy.</p>","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"12 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10768781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139377364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}